Clinical trials: Treatment-as-usual
Depressive Disorder
Study to Evaluate the Safety and Efficacy of PEER Interactive Versus Treatment as Usual in Subjects With a Primary Diagnosis of Depression
This is a prospective, multicenter, randomized, double-blind, controlled study to evaluate the effectiveness of PEER Interactive to inform treatment in subjects with a primary diagnosis of depression with comorbidity of…
- Trial name
- NCT01794559
- Testing
- PEER Interactive Report
- Where
- 2 sites in United States
- Volunteers
- 1,922 people
- Sponsor
- MYnd Analytics
Dyslipidemias
Study to Evaluate the Safety of the Fixed-dose Combination Rosuvastatin/Ezetimibe for Patients With Dyslipidaemia
Retrospective, analytical, longitudinal, multicenter study to evaluate the safety of the fixed-dose combination of rosuvastatin / ezetimibe as treatment for patients with dyslipidemia in routine medical practice.
- Trial name
- TREZETE (NCT04862962)
- Testing
- Rosuvastatin 10 or 20mg /Ezetimibe 10 mg Fixed Dose
- Where
- Mexico
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Laboratorios Silanes S.A. de C.V.
Asthma
Evaluation of Tiotropium 5 µg/Day Delivered Via the Respimat® Inhaler Over 48 Weeks in Patients With Severe Persistent Asthma on Top of Usual Care (Study I)
The trial is a randomised, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of 5 µg tiotropium over a 48-week treatment period as compared to placebo.
- Trial name
- NCT00772538
- Testing
- tiotropium 5mcg/day
- Where
- 73 sites in United States, Australia and 12 more
- Volunteers
- 459 people
- Sponsor
- Boehringer Ingelheim
Schizophrenia
Neurocognitive Training Integrated in OPUS Treatment Versus OPUS Treatment-as-usual
The study examines the effect of cognitive training on cognitive functioning and everyday competencies of patients with schizophrenia.
- Trial name
- NEUROCOM (NCT00472862)
- Testing
- Cognitive training
- Where
- Denmark
- Volunteers
- 117 people
- Sponsor
- Neurocom
Asthma
Efficacy and Safety of 2 Doses of Tiotropium Respimat® Compared to Placebo in Children With Severe Persistent Asthma
The overall purpose of the trial is to evaluate efficacy and safety of tiotropium inhalation solution (2.5 mcg and 5 mcg) delivered via Respimat® inhaler once daily in the evening over 12 weeks, compared to placebo, as add-on…
- Trial name
- NCT01634152
- Testing
- Tiotropium low dose mcg, Tiotropium high dose
- Where
- 94 sites in United States, Argentina and 15 more
- Volunteers
- 401 people
- Sponsor
- Boehringer Ingelheim
Major Depressive Disorder
Pharmacogenomics for Antidepressant Guidance and Education 1 (PAGE-1_AG1)
One-third or more of individuals treated for major depressive disorder (MDD) do not experience remission of symptoms despite at least two adequate antidepressant trials.
- Trial name
- PAGE-1_AG1 (NCT01426516)
- Testing
- Genecept Assay
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Genomind, LLC
Chronic Insomnia, Cancer
Impact of Homeopathy for Persistent Insomnia in Patients With Cancer
Persistent insomnia is highly prevalent complaint in cancer survivors, but is seldom satisfactorily addressed. The adaptation to cancer care of a validated, cost-effective intervention may offer a practicable solution.
- Trial name
- NCT02515006
- Testing
- Homeopathy Medicine
- Where
- 2 sites in India
- Volunteers
- 160 people
- Sponsor
- Adwin Life Care
Major Depressive Disorder
Genecept Assay™ vs. Treatment-as-Usual to Evaluate Efficacy of Assay-Guided Treatment in Adults With MDD
In this randomized clinical trial, subjects will be assigned to either an assay-guided treatment condition (AGT) or a treatment-as-usual condition (TAU).
- Trial name
- NCT02634177
- Testing
- Assay-guided treatment (AGT), Treatment-as-usual (TAU)
- Where
- 23 sites in United States
- Volunteers
- 305 people
- Sponsor
- Genomind, LLC
Opioid-use Disorder, Opioid Misuse
Comparing a Patient Self-Assessment Software to Treatment as Usual in Opioid Prescriber and Patient Opioid Outcomes
The Care Continuity Program (CCP), a product of Sure Med Compliance, is a novel, online patient self-assessment used by prescribers of opioids to better identify patient risk factors and therapy benefit.
- Conditions
- Opioid-use Disorder, Opioid Misuse, Opioid Use, Chronic Pain
- Trial name
- NCT04945525
- Testing
- Care Continuity Program
- Where
- United States
- Volunteers
- 1,840 people
- Sponsor
- Sure Med Compliance